Daiichi Sankyo (OTCMKTS:DSNKY) Sets New 52-Week Low - Here's Why

Key Points

• Daiichi Sankyo hit a new 52-week low of $17.14 on Monday, last trading at $17.31 (down ~1.6%) with light volume, and the stock sits below its 50‑day ($18.51) and 200‑day ($21.41) moving averages.
• In the most recent quarter the company reported $0.30 EPS, beating estimates of $0.25 but missing on revenue at $3.65B versus $3.88B expected; net margin was 14.83% and return on equity 18.64%.
• Daiichi Sankyo has a conservative balance sheet (debt‑to‑equity 0.18, current ratio 2.69), a market cap of $32.74B, and trades at a P/E of 15.86 with a PEG of 0.91.

Daiichi Sankyo Co., Ltd. - Sponsored ADR (OTCMKTS:DSNKY - Get Free Report)'s share price hit a new 52-week low during trading on Monday . The company traded as low as $17.14 and last traded at $17.31, with a volume of 1861 shares. The stock had previously closed at $17.77.

Daiichi Sankyo Trading Down 1.6%

The company has a debt-to-equity ratio of 0.18, a current ratio of 2.69 and a quick ratio of 1.85. The stock has a market capitalization of $32.74 billion, a price-to-earnings ratio of 15.86, a PEG ratio of 0.91 and a beta of -0.04. The business has a 50 day simple moving average of $18.51 and a 200-day simple moving average of $21.41.

Daiichi Sankyo (OTCMKTS:DSNKY - Get Free Report) last posted its earnings results on Thursday, January 29th. The company reported $0.30 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.25 by $0.05. Daiichi Sankyo had a return on equity of 18.64% and a net margin of 14.83%.The firm had revenue of $3.65 billion during the quarter, compared to analysts' expectations of $3.88 billion. As a group, equities analysts expect that Daiichi Sankyo Co., Ltd. - Sponsored ADR will post 0.73 earnings per share for the current year.

About Daiichi Sankyo

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.